First Week Of August 2015 Options Trading For Endologix
at The Street - Wed Dec 24, 12:00PM CST
Investors in Endologix Inc. saw new options begin trading this week, for the August 2015 expiration.
ELGX: 15.35 (-0.06)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 13.13 (+0.07), SPNC: 34.50 (+0.59), ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), TRIV: 13.47 (-0.40), VOLC: 17.95 (+0.02), STJ: 66.67 (+0.67), THOR: 32.81 (+0.74), HTWR: 72.62 (+0.02), ELGX: 15.35 (-0.06), ATRC: 18.76 (+0.13), NVDQ: 16.90 (+0.55)
Insider Trading Alert - MKSI, QTWW And ELGX Traded By Insiders
at The Street - Tue Dec 16, 10:45AM CST
Stocks with insider trader activity include MKSI, QTWW and ELGX
QTWW: 2.39 (-0.01), MKSI: 37.24 (-0.01), ELGX: 15.35 (-0.06)
Endologix to Participate in Two Investor Conferences in December
GlobeNewswire - Tue Nov 25, 8:07AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at two investor conferences in December. The first conference is the 26th Annual Piper Jaffray Healthcare Conference in New York, NY.
ELGX: 15.35 (-0.06)
Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at 2014 VEITH Symposium
GlobeNewswire - Thu Nov 20, 9:11AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of initial clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms ("AAAs"
ELGX: 15.35 (-0.06)
Endologix Completes Patient Enrollment in the Nellix(R) EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Nov 18, 6:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the Company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System"
ELGX: 15.35 (-0.06)
Post Earnings Update: Endologix Has Climbed 2.1% Higher in Past 2 Weeks (ELGX)
Comtex SmarTrend(R) - Mon Nov 17, 4:01PM CST
18 days ago, on October 30th, 2014, Endologix (NASDAQ:ELGX) reported its earnings. Analysts, on average, expected a loss of $0.13 per share on sales of $37.0 million. Endologix actually reported a loss of $0.13 per share on sales of $37.2 million, beating EPS estimates by $0.00 and matching revenue estimates. Shares of Endologix have climbed from $11.24 to $11.48, representing a gain of 2.1% since the company reported earnings 18 days ago.
ELGX: 15.35 (-0.06)
Endologix to Participate in Three Investor Conferences in November
GlobeNewswire - Thu Nov 06, 4:17PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at three investor conferences in November. The first conference is the Stephens 2014 Fall Conference in New York, NY.
ELGX: 15.35 (-0.06)
InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST
VR: 41.51 (+0.19), JBHT: 84.91 (-0.02), FCX: 22.91 (+0.07), BBY: 38.89 (-0.80), NS: 57.17 (+0.24), LL: 63.91 (-0.41), ELGX: 15.35 (-0.06), ENFC: 14.42 (+0.01), RCL: 82.36 (+0.16), LMCA: 34.41 (+0.18), SPW: 86.64 (-0.11), OPK: 9.63 (+0.21), BIOL: 2.63 (-0.07), IMI: 1.98 (-0.02), NHF: 11.23 (+0.01), SIX: 42.72 (+0.16), TWTR: 37.61 (+0.04), SCHW: 30.67 (+0.01)
Endologix to Host Investor Meeting on Thursday, November 20, 2014
GlobeNewswire - Mon Nov 03, 8:36AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2014 investor meeting, which will be held on November 20, 2014 from 5:00 to 7:30 pm ET at the New York Hilton Midtown. The event will include a Company update, presentations from prominent physicians and a question and answer session with the physicians and Endologix management
ELGX: 15.35 (-0.06)
More on Endologix Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 4:01PM CDT
ELGX: 15.35 (-0.06)
Endologix meets 3Q profit forecasts
Automated Insights - Fri Oct 31, 4:03AM CDT
IRVINE, Calif. (AP) _ Endologix Inc. (ELGX) on Friday reported a third-quarter loss of $13.9 million.
ELGX: 15.35 (-0.06)
Endologix's (ELGX) CEO John McDermott on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:54PM CDT
ELGX: 15.35 (-0.06)
Endologix EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:02PM CDT
ELGX: 15.35 (-0.06)
Endologix (ELGX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT
ELGX: 15.35 (-0.06)
Endologix Reports 12% Global Revenue Growth for the Third Quarter 2014
GlobeNewswire - Thu Oct 30, 3:50PM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2014.
ELGX: 15.35 (-0.06)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT
ELLI: 41.40 (+0.81), AIV: 37.80 (-0.33), EPAY: 25.23 (-0.04), CPSI: 61.11 (-0.09), LNKD: 231.83 (+0.34), ADNC: 4.15 (+0.01), CODE: 34.55 (+0.64), HME: 66.47 (-0.43), ESIO: 7.76 (+0.13), HIL: 3.69 (-0.05), DGI: 30.85 (+0.27), AHT: 10.87 (-0.04), COLM: 44.76 (-0.62), AHS: 19.89 (+0.14), CSLT: 12.14 (+0.30), FRT: 136.26 (-0.13), DGII: 9.15 (+0.15), ADUS: 23.80 (-0.19), ESS: 210.72 (-1.86), EXPE: 89.01 (+0.09), IMPV: 51.87 (+1.18), CCI: 79.05 (-0.13), CPT: 75.44 (-0.56), GB: 49.34 (-0.36), AEGR: 21.59 (-0.27), ATEN: 4.29 (+0.01), ELGX: 15.35 (-0.06), AFFX: 9.80 (+0.05), CHE: 106.16 (+0.13), BCOV: 7.88 (-0.05), DCT: 35.96 (+0.21), ELX: 5.75 (+0.03), GNMK: 13.67 (+0.06), AXTI: 2.65 (-0.09), INT: 47.79 (-0.05), EGN: 64.33 (-0.02), EGO: 5.97 (+0.18), GMED: 24.37 (+0.44), GDOT: 20.42 (+0.25), KEG: 1.73 (+0.01), ISBC: 11.14 (+0.04), GRPN: 7.89 (-0.14), ALJ: 12.54 (+0.04), CTRL: 14.57 (-0.04), GPRO: 66.41 (+4.87), EMN: 76.80 (+0.04), IMMR: 9.45 (+0.47), CUBE: 22.59 (+0.08), BYI: 83.27 (unch), ATRC: 18.76 (+0.13), BYD: 12.28 (+0.14), FLDM: 32.31 (+0.30), BEAT: 10.15 (+0.09), FLR: 60.30 (-0.26), FLT: 149.17 (-0.93), EHTH: 27.13 (+0.97)
Endologix to Report Third Quarter 2014 Financial Results on October 30, 2014
GlobeNewswire - Thu Oct 09, 8:36AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2014 financial results, which will take place on Thursday October 30, 2014 after the close of the market.
ELGX: 15.35 (-0.06)
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.87 (+0.04), ECYT: 6.33 (+0.24), PDFS: 14.97 (+0.03), CTCM: 4.89 (-0.20), WRES: 1.66 (-0.13), ADHD: 4.00 (+0.24), RTRX: 12.92 (+0.19), GWGH: 8.04 (-0.07), MTEX: 28.96 (unch), ELGX: 15.35 (-0.06), DWSN: 11.40 (+0.70), OTIC: 32.26 (+0.65), THRM: 38.25 (-0.11)
Nasdaq stocks posting largest volume increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PDFS: 14.97 (+0.03), IKAN: 0.31 (-0.01), SANW: 3.98 (-0.02), TIBX: 24.03 (+0.03), ALIM: 5.43 (-0.06), MOVE: 20.95 (-0.03), SPEX: 1.11 (+0.04), MBTF: 4.85 (+0.04), ELGX: 15.35 (-0.06), SMPL: 16.95 (+0.03)